IATDMCT 2017

Session information

Poster

[P26-8] P26-8: Oncologic drugs (4): Pharmacokinetics, TDM practice

Tue. Sep 26, 2017 12:30 PM - 1:30 PM Annex Hall (1F)

Chair: Kohji Naora, Japan

Emiko Miyahara1, Takuro Nishikawa2, Kazuro Ikawa3, Miharu Ushikai4, Hiroaki Kawaguchi5, Yasuhiro Okamoto6, Norifumi Morikawa7, Masahisa Horiuchi8, Yoshifumi Kawano9 (1.Kagoshima University, 2.Kagoshima University, 3. Hiroshima University, 4. Kagoshima University, 5. Kagoshima University, 6. Kagoshima University, 7. Hiroshima University, 8. Kagoshima University, 9. Kagoshima University)

Takuro Nishikawa1, Kazuro Ikawa2, Emiko Miyahara3, Takanari Abematsu4, Shunsuke Nakagawa5, Koichiro Kurauchi6, Yuichi Kodama7, Takayuki Tanabe8, Yuichi Shinkoba9, Yasuhiro Okamoto10, Norifumi Morikawa11, Yoshifumi Kawano12 (1.Kagoshima University, 2.Hiroshima University, 3.Kagoshima University, 4.Kagoshima University, 5.Kagoshima University, 6.Kagoshima University, 7.Kagoshima University, 8.Kagoshima University, 9.Kagoshima University, 10.Kagoshima University, 11.Kagoshima University, 12.Kagoshima University)

Masaki Hirabatake1, Tomoyuki Mizuno2, Rieko Miura3, Eri Hohokabe4, Sayaka Takebe5, Kazuki Hashimoto6, Yuichiro Kikawa7, Hironori Kato8, Thoru Hashida9 (1.Kobe City Medical Center General Hospital, 2.Cincinnati Children’s Hospital Medical Center, 3.Kobe City Medical Center General Hospital, 4.Kobe City Medical Center General Hospital, 5.Kobe City Medical Center General Hospital, 6.Kobe City Medical Center General Hospital, 7.Kobe City Medical Center General Hospital, 8.Kobe City Medical Center General Hospital, 9.Kobe City Medical Center General Hospital)

Akitomo Yokokawa1, Shun Kaneko2, Sayuri Endo3, Ryohei Hirano4, Fumio Nagashima5, Daisuke Naruge6, Naohiro Okano7, Takaaki Kobayashi8, Kirio Kawai9, Junji Furuse10, Hiromi Shibasaki-Hirano11, Takashi Furuta12 (1.Tokyo University of Pharmacy and Life Sciences, 2.Tokyo University of Pharmacy and Life Sciences, 3.Tokyo University of Pharmacy and Life Sciences, 4.Tokyo University of Pharmacy and Life Sciences, 5.Kyorin University, Faculty of Medicine, 6.Kyorin University, Faculty of Medicine, 7.Kyorin University, Faculty of Medicine, 8.Kyorin University, Faculty of Medicine, 9.Kyorin University, Faculty of Medicine, 10.Kyorin University, Faculty of Medicine, 11.Tokyo University of Pharmacy and Life Sciences, 12.Tokyo University of Pharmacy and Life Sciences)

Takeshi Aoyama1, Takako Karaki2, Kazuyuki Ito3, Keiichi Azuma4, Koki Hashimoto5, Ryota Furutani6, Kazuyoshi Kawakami7, Kenichi Suzuki8, Kenji Nakano9, Junichi Tomomatsu10, Naoki Fukuda11, Takeshi Yuasa12, Erika Sugiyama13, Hitoshi Sato14, Shunji Takahashi15, Toshihiro Hama16 (1.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 2.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 4.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 5.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 6.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 7.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 8.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 9.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 10.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 11.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 12.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 13.Showa University, 14.Showa University, 15.The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 16.The Cancer Institute Hospital, Japanese Foundation for Cancer Research)